Chemical formula: C₂₃H₂₉N₃O Molecular mass: 363.505 g/mol PubChem compound: 9417
Opipramol has high affinity for the sigma binding sites (type 1 and type 2) and has an antagonistic effect at the type 1 histamine receptors. The affinity for the type 2A serotonin receptors, type 2 dopamine receptors and the α-adrenergic receptors is lower. In contrast to the structurally related tricyclic antidepressants, opipramol has only slight anticholinergic activity and does not inhibit the reuptake of serotonin or noradrenaline. In humans, opipramol has sedating, anxiolytic and slight mood-elevating effects.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AA05 | Opipramol | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| SYMPRAMOL Coated tablet | MPI, EU: SmPC |
Opipramol is an active ingredient of these brands:
Austria (AT)
Germany (DE)
Poland (PL)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
